AbCellera Biologics (NASDAQ:ABCL – Get Free Report) and Swedish Orphan Biovitrum (OTCMKTS:BIOVF – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.
Profitability
This table compares AbCellera Biologics and Swedish Orphan Biovitrum’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AbCellera Biologics | -218.54% | -15.35% | -10.84% |
| Swedish Orphan Biovitrum | 20.67% | 17.92% | 9.30% |
Insider and Institutional Ownership
61.4% of AbCellera Biologics shares are held by institutional investors. 28.4% of AbCellera Biologics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares AbCellera Biologics and Swedish Orphan Biovitrum”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| AbCellera Biologics | $75.13 million | 49.95 | -$146.41 million | ($0.48) | -23.94 |
| Swedish Orphan Biovitrum | $2.89 billion | 6.30 | $48.85 million | $2.01 | 25.40 |
Swedish Orphan Biovitrum has higher revenue and earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Swedish Orphan Biovitrum, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
AbCellera Biologics has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500. Comparatively, Swedish Orphan Biovitrum has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current recommendations for AbCellera Biologics and Swedish Orphan Biovitrum, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AbCellera Biologics | 1 | 1 | 7 | 2 | 2.91 |
| Swedish Orphan Biovitrum | 0 | 3 | 5 | 0 | 2.62 |
AbCellera Biologics currently has a consensus price target of $16.20, suggesting a potential upside of 40.99%. Given AbCellera Biologics’ stronger consensus rating and higher possible upside, research analysts clearly believe AbCellera Biologics is more favorable than Swedish Orphan Biovitrum.
Summary
AbCellera Biologics beats Swedish Orphan Biovitrum on 8 of the 15 factors compared between the two stocks.
About AbCellera Biologics
AbCellera Biologics Inc. is a biotechnology company headquartered in Vancouver, Canada. It discovers and develops antibody-based medicines, using laboratory and computational tools to identify and optimize antibodies that may be developed into treatments for disease. The company works with pharmaceutical and biotechnology partners on antibody discovery and drug development, while also advancing a portfolio of its own therapeutic candidates. Its work spans early-stage research through preclinical and clinical development, with programs focused on areas including cancer and immune-related diseases.
About Swedish Orphan Biovitrum
Swedish Orphan Biovitrum AB, known as Sobi, is a Swedish biopharmaceutical company focused on developing and providing treatments for rare and other serious diseases. Its work centers on hematology, immunology and specialized medicines for conditions with limited treatment options. Sobi’s portfolio includes therapies for blood disorders such as hemophilia, as well as treatments for rare inflammatory and immune-related conditions. The company also develops and commercializes medicines for other rare diseases, working with research and commercial partners where appropriate.
Receive News & Ratings for AbCellera Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbCellera Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
